


Francis Worden,¹ Cristina Rodriguez,² Amita Patnaik,³ Justin Call,⁴ A. Dimitrios Colevas,⁵ Ammar Sukari,⁶ Trisha Wise-Draper,⁷ Nabil F. Saba,⁸ Koho lizuka,⁹ Hong Tang,⁹ Varun N Kapoor,⁹ Douglas Adkins¹⁰


¹University of Michigan, Ann Arbor, MI, USA; ⁴START Center for Cancer Research, Salt Lake City, UT, USA; ⁵Stanford Cancer Institute, Stanford, CA, USA; ⁴START Center for Cancer Research, Salt Lake City, UT, USA; ⁵Stanford Cancer Institute, Stanford, CA, USA; ⁴START Center for Cancer Research, Salt Lake City, UT, USA; ⁵Stanford Cancer Research, Salt Lake City, UT, USA; ⁵Stanford Cancer Research, San Antonio, TX, USA; ⁴START Center for Cancer Research, Salt Lake City, UT, USA; ⁵Stanford Cancer Research, San Antonio, TX, USA; ⁴START Center for Cancer Research, Salt Lake City, UT, USA; ⁵Stanford Cancer Research, Salt Lake City, UT, USA; ⁵Stanford Cancer Research, Salt Lake City, UT, USA; ⁴START Center for Cance ⁶Barbara Ann Karmanos Cancer Institute, Farmington Hills, MI, USA; ⁹Coherus BioSciences, Redwood City, CA, USA; ¹⁰Washington University, St. Louis, MO, USA


BACKGROUND

- C-C motif chemokine receptor 8 (CCR8) is a G-protein coupled receptor that highly expressed on tumor-infiltrating T regulatory cells (Tregs)¹
- Intratumoral CCR8+ Tregs are highly immunosuppressive, enriched in the tumor microenvironment (TME) and frequently associated with a lack of response to immunotherapy, therefore selective depletion of intratumoral Tregs is an attractive immunotherapy strategy²
- Strong scientific rationale for targeting CCR8 in head and neck squamous cell carcinoma (HNSCC) and other solid tumors:
- CCR8+ Tregs are most abundant in HNSCC, cervical squamous cell carcinoma (SCC), and gastric cancer, and broadly expressed in several solid tumors, including colorectal cancer (CRC) and lung cancer
- Radiation and PD-1 blockade on Tregs are known to increase Tregs, supporting the use of anti-CCR8 with anti-PD-1 agents
- CHS-114 is a selective, cytolytic anti-CCR8 monoclonal antibody (mAb) with no off-target binding³
- CHS-114 has the potential to overcome Treg-mediated immune suppression within the TME by recruiting T cells, turning cold tumors to hot, and enhancing antitumor immunity when combined with other immuno-oncology (IO) agents such as the anti-PD-1 antibody, toripalimab⁴





isotope control) was calculated. EC_{50} values of CHS-114 were calculated based on 4-1BB induction on NK cells. C-D) PBMCs were treated with increasing concentrations of CHS-114 at 37°C for 16 hours. The frequency of B7-H3 and CD83 expressing monocytes was determined by flow cytometry. EC₅₀ values of CHS-114 were calculated based on B7-H3 frequency (C) and CD83 frequency on monocytes (D). Based on the above, in vitro pharmacology data target trough levels for the expected pharmacological activity in participants treated with CHS-114 in clinical trials were defined.





Density (y-axis) vs frequency (x-axis) of CCR8+ Treas (of total FOXP3-Treas) in tumor microarrays from 12 types of solid tumors evaluated by a mIF assay. Tumor types in which clinical benefit has been observed with anti-CCR8 antibodies (CHS-114-101 study or competitor trials) are highlighted (red circles). For evaluating CCR8+ Tregs, CCR8 and FOXP3 staining was performed.






- A Phase 1, first-in-human (FIH), open-label single-agent and combination dose trial was initiated to evaluate CHS-114 in patients with advanced solid tumors and HNSCC. During monotherapy dose escalation (Stage 1a):⁵
- CHS-114 demonstrated an acceptable safety profile in heavily pre-treated patients with advanced solid tumors, with no DLTs reported to date and generally low-grade treatment-emergent adverse events (TEAEs)
- There were no complete or partial responses, but 47.4% of patients had stable disease (SD); one patient with SD >12 months remains on study
- Pharmacokinetic (PK) exposure increased with dose, was approximately dose proportional, and the elimination appeared linear with a half-life of about 10 days (range 9-17 days)
- Depletion of peripheral CCR8+ Tregs was observed (>85% in the periphery) and depletion was maintained over the dosing interval, establishing proof of mechanism; CHS-114 did not deplete non-CCR8+ Tregs and effector CD4 T cells (proof of specificity) • Two doses were selected for dose optimization based on safety, peripheral CCR8+ Treg depletion, PK and biomarker data

METHODS

- A Phase 1, FIH, open-label single-agent and combination dose trial to evaluate CHS-114 in patients with advanced solid tumors and HNSCC (NCT05635643)
- Here we report CHS-114 monotherapy and combination results in the HNSCC patients enrolled in the trial as of the January 24, 2025, data cutoff date




Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors


cytotoxicity **(GZMB, C)** in PBMC samples were measured by Cytek FACS assay at indicated time points. An increase in IFNy and CD8+ T cell activation (Ki67, GZMB) compared t pre-treatment levels was observed through one dosing cycle for participants enrolled in CHS-114-101 monotherapy dose escalation and HNSCC dose expansion (only select participants from HNSCC dose expansion). Furthermore, IFNy induction and CD8+ T cell activation was sustained at DL5 and higher doses supportive of a pharmacologically and biologically active dose. Participants with longitudinal samples are plotted (C1D1 and C2D1); N's based on number of participants at baseline. Thick solid and dashed lines represen median values for groups defined in the legend; thin dashed lines represent individual

	CHS-114 Monotherapy	Cteristics CHS-114 + Toripalimab
	(n=14†)	(n=7)
ge, median years (range)	67 (42, 88)	67 (49, 79)
Gender, n (%) Female Male	3 (21.4) 11 (78.6)	2 (28.6) 5 (71.4)
Race, n (%) American Indian or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islander White	0 0 2 (14.3) 0 12 (85.7)	0 0 0 7 (100.0)
Unknown Other Not Reported	0 0 0	0 0 0
ECOG, n (%) 0 1 Accientime since initial diagnosis menths (range)	4 (28.6) 10 (71.4)	5 (71.4) 2 (28.6)
Median time since initial diagnosis, months (range) Lines of prior systemic therapy, n (%) 0 1-2 3-4 ≥5	25.5 (11, 184) 1 (7.1) 7 (50.0) 5 (35.7) 1 (7.1)	21 (15, 84) 0 5 (71.4) 2 (28.6) 0
PD-L1 expression*, n (%) Positive Negative Not Done	13 (92.9) 1 (7.1) 0	7 (100.0) 0 0


*Patients with HNSCC from stage 1a (n=2) and stage 1b (n=12 *PD-L1 expression measured by combined positive score (CPS) or tumor proportion score (TPS



Confirmed Partial Response in Target Lesions




HNSCC Time on Treatment




Safety Summary in HNSCC				
AE Summary	CHS-114 Monotherapy (n=14)	CHS-114 + Toripalimab (n=7)		
Treatment-emergent adverse event (TEAE), n (%)	12 (85.7)	7 (100.0)		
Treatment-related ⁺ AE, n (%)	7 (50.0)	7 (100.0)		
Grade ≥3 TEAE, n (%)	4 (28.6)	5 (71.4)		
Grade ≥3 treatment-related† AE, n (%)	1 (7.1)	4 (57.1)		
Serious treatment-emergent adverse event (TESAE), n (%)	3 (21.4)	3 (42.9)		
Treatment-related ⁺ SAE, n (%)	0	0		
TEAE leading to study drug(s) discontinuation*, n (%)	0	4 (57.1)		
Treatment-related ⁺ AE leading to CHS-114 discontinuation [*] , n (%)	Ο	2 (28.6)		
TEAE leading to death, n (%)	0	Ο		
Treatment-related ⁺ AE leading to death, n (%)	0	0		

For monotherapy with HNSCC. treatment-related AEs are CHS-114-related AE; For stage 2 subjects, treatment-related AE are CHS-114 and/or toripalimab related AEs. *For stage 2 subjects, treatment discontinuation are CHS-114 and/or toripalimab discontinuation



Follow-up 3



LA: ~0.5 cm


RECIST Assessment:


- Target lesions: 40.0% reduction in the target lesions at the time of confirmed PR at follow-up 3
- Non-target lesions: 2 out of 4 non-target lesions disappeared after 2 treatment cycles
- No new lesions


Responder Demographics:


- Oropharyngeal squamous cell carcinoma (OPSCC)
- P16 positive, PD-L1 CPS 4, and TMB 8 mut/Mb
- CDKN2A, EGFR. Mutations: NOTCH, PIK3CA
- Patient was diagnosed at Stage 4 and refractory to 3 prior lines of systemic therapy including anti-PD-1 (~12 mo from 1L αPD-1 plus chemo)


RESULTS











- remodeling and establishing proof of mechanism
- drugs such as T cell engagers and bispecifics

REFERENCES: 1. Kidani Y, et al. Proc Natl Acad Sci USA. 2022;119(7):e2114282119. 2. Haruna M, et al. Sci Rep. 2022;12(1):5377. 3. Wang X, et al. J Immunother Cancer. 2024;12(Suppl 2):A1-A1683. 4. Rajasekaran N, et al. Int J Radiat Oncol Biol Phys. 2024;118(5):e89. 5. Patnaik A, et al. J Clin Oncol. 2024;42(suppl 16):2664. **DISCLOSURE:** Study sponsored by Coherus BioSciences. Corresponding author email address: fworden@med.umich.edu. ACKNOWLEDGMENTS: The authors would like to thank the patients who are participating in this study, their families and caregivers, as well as the investigators and study teams at all clinical sites.



Abstract Presentation **#CT038**



CONCLUSIONS

• Two doses were selected for dose optimization based on safety, peripheral CCR8+ Treg depletion, PK and biomarker data; these two doses are supported by the observed immune activation in blood and CCR8+ Treg depletion in tumor

• CHS-114 with and without toripalimab had a manageable safety profile in HNSCC patients

• CHS-114 with toripalimab had promising antitumor activity in HNSCC that warrants continued exploration

• In on-treatment tumor biopsies, CHS-114 depleted CCR8+ Tregs and increased CD8+ T cells in the TME indicating favorable TME

- CHS-114 administration leads to a substantial increase in CD8+ T cells in the TME providing a strong rationale for combining with other

• All together, these data support further evaluation of CHS-114 in combination with other drugs including toripalimab; a second-line (2L) HNSCC CHS-114 with toripalimab dose optimization study is ongoing